Efficacy

Efficacy of Rukobia (fostemsavir)

Rukobia (fostemsavir) is an antiretroviral medication specifically designed for the treatment of HIV/AIDS in adults with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen. As an attachment inhibitor, fostemsavir targets the first step of the viral cycle by preventing the virus from binding to host CD4+ T cells. Clinical trials have demonstrated its efficacy in significantly reducing viral load and increasing CD4+ T cell counts in a population of heavily treatment-experienced individuals with limited treatment options.

In the pivotal phase 3 BRIGHTE study, patients treated with Rukobia in combination with an optimized background therapy showed a meaningful reduction in HIV-1 RNA levels at week 96 compared to baseline. The study underscored Rukobia's role in providing a viable treatment pathway for patients who have developed resistance to multiple HIV medication classes and have few remaining options to manage their infection effectively.

Efficacy of Cabenuva (cabotegravir + rilpivirine)

Cabenuva is a combination injectable treatment regimen consisting of cabotegravir, an integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI). It is indicated for the treatment of HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine. Cabenuva's long-acting formulation allows for once-monthly or every-two-months dosing, which is a significant shift from the daily oral regimens traditionally used in HIV treatment.

The efficacy of Cabenuva as a long-acting, injectable regimen has been demonstrated in the pivotal ATLAS and FLAIR phase 3 studies. These studies showed that Cabenuva was as effective as daily oral three-drug regimens in maintaining viral suppression over a 48-week period. The long-term efficacy data also support its use, with ongoing viral suppression observed in extended follow-up periods. This novel treatment approach has been hailed as a game-changer, offering patients with HIV/AIDS an alternative to daily oral medication and the potential to improve adherence and quality of life.